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Objective: Carbon monoxide (CO) and nitric oxide (NO) have both been shown to possess vasoprotective properties. NO has
successfully inhibited intimal hyperplasia in both small-animal and large-animal experimental models, whereas CO has only been
studied in rodents. Evidence suggests that these two molecules may exert their vascular effects through common as well as unique
signaling pathways. The purpose of this study was to determine the effect of a low concentration of inhaled CO on intimal
hyperplasia in a large-animal model and if CO and NO treatment could exert a synergistic effect to inhibit this process.
Methods: Balloon angioplasty was performed in a porcinemodel. Animals received inhaled CO (250 ppm) delivered preoperatively
for 60minutes or preoperatively and intraoperatively. Bloodwas collected for carboxyhemoglobin (COHgb)measurements at the
startof theoperationandevery30minutesduring theoperation.Heart rate, respiratory rate, andoxygen saturationweremonitored
throughout.To study the effect of combinedCOandNOtreatment, another groupof pigs received inducibleNOsynthase (iNOS)
gene transfer in one iliac artery and control gene transfer (AdlacZ) in the contralateral iliac artery, with orwithout preoperative and
intraoperative inhaled CO. Adenoviral infection was performed immediately after balloon injury. All animals were euthanized at 3
weeks, and iliac arteries were collected for histologic and morphometric analysis.
Results: One hour of pretreatment with CO was associated with modest and transient elevations in COHgb levels, resulting in a
25.6% reduction in neointimal area and a 10% reduction in intimal area/medial area ratio (I/M) 3 weeks after injury (NS). In
contrast, preoperative followed by intraoperative CO administration increased COHgb in a sustained fashion and inhibited
neointima formation by 51.7% and I/M by 31% (P< .001). There was no evidence of toxicity associated with this administration
ofCO.The treatment of injured iliac arterieswith the control adenoviral vectorAdlacZdid not further increase the inhibitory effect
ofCOon intimal hyperplasia.The combinationof inhaledCOand iNOSgene transfer resulted ingreater protection, however,with
a 64% reduction in neointimal area and a 48% reduction in I/M (P< .001).
Conclusions:COisaneffectivemeansof reducing intimalhyperplasia in largeanimals after vascular injurywhendeliveredduring the
operative procedure.No toxicity was associatedwith the increase inCOHgb. The combination of CO andNOprovided additional
protectionagainst thevascular injury response,withagreater reduction inneointima formation.Thesedata suggest that these agents
may prove to be clinically beneficial in prolonging vascular patency after interventions. (J Vasc Surg 2006;44:151-8.)
Clinical Relevance: Intimal hyperplasia is a significant clinical problem that greatly reduces the long-term patency of surgical
bypasses and angioplasty/stent procedures. Carbon monoxide (CO) is an emerging tool in the prevention of intimal hyperplasia
after vascular injury.We demonstrated in a porcinemodel of vascular injury that the preoperative and intraoperative administration
of inhaled CO significantly reduced neointima formation. In addition, CO showed synergistic effects when combined with nitric
oxide (NO) synthase gene therapy, a treatment that hadbeenpreviously shown to significantly reduce intimal hyperplasia.Themain
clinical relevance of this study is that, to our knowledge, it is the first large-animalmodel study to show thebenefit of inhaled carbon
monoxide on vascular injury. Further studies are required to further hone the optimal dosing regimen of CO and the potential of
combined CO/NO therapy.From the Department of Surgery at University of Pittsburgh,a Beth Israel
Deaconess Medical Center,b and Department of Pulmonary Medicine,c
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ered an environmental toxin and silent killer. The unveiling
of CO’s therapeutic potential originated from studies of
heme oxygenase 1 (HO-1), which is expressed by many
tissues after injury or inflammation. HO-1 catabolizes
heme to biliverdin, free iron, and CO. HO-1 has been
associated with antioxidant and anti-inflammatory func-
tions that are important for tissue protection after organ
transplantation, endotoxemia, and hyperoxia.1-3 HO-1 ex-
pression has been documented in vascular tissues, and
inhibition of HO-1 activity has been shown to exacerbate
intimal hyperplasia induced by vascular injury.4,5 In con-
trast, over-expression of HO-1 or administration of one or
more of its products at sites of vascular injury using gene
transfer techniques significantly inhibits intimal hyperpla-
sia.6-8 The vasoprotective properties of HO-1 are partly
mediated through CO.
We have previously reported that low concentrations of
inhaled CO for a very short time dramatically reduced
intimal hyperplasia in rodents.9 Moreover, the one-time
1-hour pretreatment with no further exposures was suffi-
cient to prevent intimal hyperplasia measured 2 weeks later.
Inhaled CO delivered in a more prolonged fashion inhib-
ited immune-mediated vascular injury in a rodent model of
transplantation vasculopathy.9 CO has also been shown to
prevent vascular remodeling associated with pulmonary
hypertension in a rodent model.10
Nitric oxide (NO) is a molecule that is very similar
structurally and functionally to CO and also possesses many
vasoprotective properties. NO has antioxidant and anti-
inflammatory functions in many organs and, especially, in
the vasculature.11 We have previously demonstrated that
NO delivered using gene transfer of the inducible NO
synthase (iNOS) to injured vasculature inhibited intimal
hyperplasia significantly.12 The structural and functional
similarities between these molecules suggest the existence
of a mechanistic overlap. In addition, NO induces HO-1
expression in many different cell types. In vascular smooth
muscle cells, NO was shown to regulate HO-1 expression
and function.13
Despite these links between CO and NO, we have
demonstrated that the vasoprotective properties of CO are
mediated through cyclic guanosine monophosphate
(cGMP)-dependent pathways,9 whereas NO released after
iNOS gene transfer uses cGMP-independent mecha-
nisms.14 These findings indicate that NO and CO in the
vasculature may also function through distinct signaling
pathways.
The efficacy of inhaled CO in the inhibition of intimal
hyperplasia is clear in rodents but has not been established
in an animal model that is more representative and predic-
tive of human vascular behavior. It is unclear if CO would
be effective in large animals and humans and if a limited
exposure to CO, as seen in the rodents, would be sufficient.
In this study, we examined the dosing and efficacy of
inhaled CO for inhibiting intimal hyperplasia in a pigmodel
of vascular injury. In addition, given that NO and CO may
function through distinct signaling pathways in the vascu-lature, we evaluated the effect of combined NO/CO ad-
ministration on the vascular injury response.
METHODS
Surgical procedure. All animal procedures were per-
formed under sterile conditions in accordance with the
Institutional Animal Care and Use Committee of the Uni-
versity of Pittsburgh. Juvenile male Yorkshire pigs (n 6 to
9 per group) (Walter Whippo, Enon Valley, PA) weighing
12 to 15 kg were used. Pigs treated with COwere placed in
a chamber that delivered CO at 250 ppmmixed with room
air for 1 hour before anesthesia administration. The other
pigs were maintained on room air. Some pigs received 1
hour of pretreatment with CO or pretreatment followed by
continuous CO delivery throughout the operative proce-
dure via the endotracheal tube. Intraoperative CO was also
administered as 250 ppm mixed with room air. The pigs
that did not receive intraoperative CO received the stan-
dard 100% oxygen. Anesthesia was maintained with intra-
venous sodium pentobarbital and inhalational isoflurane.
Common iliac artery (CIA) balloon injury was created
as previously described.12 Briefly, a midline laparotomy was
performed, and the bilateral CIAs were exposed. After
proximal and distal vascular control was obtained, a 3F
embolectomy catheter was inserted through a side branch
into the CIA and inflated to 2 atm for 5 minutes. After
injury, intraluminal adenoviral vector (5  108 plaque
forming units per vessel) was instilled into the injured
segment of iliac artery after proximal and distal control was
obtained and allowed to incubate for 30 minutes.
In each pig, the right CIA was treated with AdiNOS
and the left CIA with AdlacZ. After the incubation period,
the viral solution was aspirated from the vessel, the side
branch was ligated, and flow was re-established. The site of
balloon injury was marked by 6-0 Prolene (Ethicon, Som-
erville, NJ) sutures to ensure that the appropriate segment
of artery was collected. In addition, the pigs received pre-
operative and intraoperative inhaled CO or else were main-
tained on room air and oxygen.
Blood samples were collected at 30-minute intervals
throughout the operative procedure for carboxyhemoglo-
bin (COHgb) measurements. COHgb was measured on a
CO-oximeter (Radiometer, Brønshøj, Denmark). Physio-
logic parameters were monitored and recorded by certified
veterinary technicians during the operative procedure. An-
imal weights were obtained before surgery and at the time
of euthanasia.
Adenoviral vectors. First generation E-1– and E-3–
deleted, replication-deficient adenoviral vectors were used.
The preparation of a recombinant adenoviral vector carry-
ing the human hepatocyte iNOS complimentary DNA
(AdiNOS) has been previously described.12 The control
vector carried the -galactosidase marker gene (AdlacZ).
Viral stocks were diluted to the appropriate concentration
using serum-free Optimem (Gibco, Grand Island, NY).
Tissue processing. Pigs were euthanized 21 days after
balloon injury. Animals were anesthetized and the iliac
vessels were removed with wide margins. The vessels were
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overnight in 30% sucrose at 4°C. The vessels were fixed in
TissueTek (Bayer Corporation, Pittsburgh, Penn) and
stored at –80°C until sectioned. The portion of the vessel
marked by the Prolene suture was serially sectioned (5m),
and every third section was stained with hematoxylin and
eosin. A total of 15 to 20 sections from each vessel, with the
area of greatest injury located within the middle of this
series, were imaged at fourfold magnification using an
Olympus Provis microscope (Olympus, Tokyo, Japan).
Morphometric analysis of these sections was performed
using MetaMorph software (Universal Imaging Corp,
Downingtown, Penn) as previously described.12
Statistical analysis. Data are reported  SEM. All
statistical analyses were performed using Stata (StataCorp,
College Station, Texas). The Wilcoxon matched-pair
signed-rank test was used for all pair wise comparisons of
nonparametric data. One-way analysis of variance was used
for the comparisons across the different treatment groups
for parametric data. To assess pair wise differences among
these treatment groups, the Scheffe follow-up procedure
was performed. Values of P  .05 were considered to be
statistically significant.
RESULTS
One hour of CO pretreatment inhibits intimal hy-
perplasia. We examined the effect of CO pretreatment on
balloon injury induced intimal hyperplasia at 21 days after
injury. CO-treated pigs showed a 25.3% reduction in neo-
intimal area compared with air-treated pigs (NS) (Fig 1, A,
Table I). Unlike in the rodent studies where medial area
was unchanged by CO,9 CO-treated pigs had a 17.9%
reduction in medial area (P  .05). Despite this reduction
in medial area, intima area/media (I/M) area ratios were
calculated and revealed that CO reduced the I/M ratio by
only 10% compared with air-treated pigs (Table I). The
overall reduction in postinjury blood vessel remodeling in
the pigs was much less dramatic than the 74% reduction
achieved in rats treated in a similar fashion.9
COHgb levels were measured in these pigs throughout
the operative procedure. Pigs pretreated with CO had
COHgb levels of 12.9%  1.5% at the initiation of the
operation (time  0), shortly after the animals were re-
moved from the CO chamber. Pigs maintained in room air
had COHgb levels of 4.0%  0.7% (Fig 1, B). COHgb
levels fell rapidly during the operative procedure and were
reduced by half (6.5% 1.3%) at 60 minutes after removal
from the CO chamber. By 90 minutes, COHgb levels were
near baseline levels (5.0%  1.0%).
Improved inhibition of intimal hyperplasia with
longer CO treatment. The modest inhibitory effect
achieved with 1 hour of CO pretreatment on neointima
formation may have been related to the transient rise in
COHgb. Longer CO exposure may increase COHgb levels
in a more sustained fashion, which may have a greater
inhibitory effect on neointima formation. To examine this,
CO administration was initiated 1 hour preoperatively and
continued throughout the operative procedure. The addi-tion of intraoperative COmaintained COHgb levels for the
entire duration of the operation, starting at 14.8%  2.2%
at the beginning of the operation and 15.9%  1.2% at 90
minutes (Fig 1, B). The longer exposure to CO had a
greater impact on the vascular injury response. Intimal area
was reduced by 50% (P  .001) and medial area by 26%
Fig 1. Effect of inhaled carbon monoxide (CO) on the devel-
opment of intimal hyperplasia after balloon angioplasty. A,
Quantification of intimal and medial areas 3 weeks after balloon
injury in pigs treated with 60 minutes of inhaled CO (250 ppm)
or room air before surgery. B, Carboxyhemoglobin (Carboxy
Hb) levels measured in pigs treated with air, 60 minutes of CO
pretreatment, or 60 minutes of CO pretreatment followed by
intraoperative CO administration (n  5 for all time points
except 120 minutes where n  4; arrow indicates time of
injury). C, Quantification of intimal and medial areas 3 weeks
after balloon injury in pigs treated with 60 minutes of CO
pretreatment and intraoperative CO administration versus oxy-
gen. *P  .001 vs air treated controls. Data are reported 
SEM.
Table I. Summary of the effect of carbon monoxide on
blood vessel morphometry
Treatment Intimal area Medial area
Intima/media
ratio
Pre-op air 2.25  0.14 2.96  0.22 0.77  0.03
Pre-op CO 1.68  0.12 2.43  0.09 0.69  0.05
Pre/intra-op air 1.84  0.06 2.49  0.10 0.75  0.03
Pre/intra-op CO 0.92  0.15* 1.84  0.06* 0.52  0.09†
CO, Carbon monoxide.
Statistical analysis by one-way analysis of variance. Data are presented as
mean  standard error.
*P  .001 vs Pre-op air, Preop CO, Pre/intra-op air.
†P  .001 vs Pre-op air, Pre/intra-op air; P  .01 vs Pre-op CO.(P .001) compared with animals that did not receive CO
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a reduction in the I/M ratio by 31% by preoperative and
intraoperative CO (P  .001) compared with air treated
animals and 24% compared with animals treated with only
preoperative CO (P  .006). These results support the
greater reduction in neointima formation by the longer
duration of CO exposure and sustained elevations in CO-
Hgb levels.
Physiologic effects of CO administration. One of
the concerns about CO administration as a therapeutic
agent is toxicity resulting from diminished oxygen-carrying
capacity. The pigs were monitored hemodynamically
throughout the operative procedure (Table II). Heart rate
and oxygen saturation were monitored, and no significant
differences were noted in these parameters between pigs
treated with CO and those treated with oxygen. Similarly,
no difference was found between pigs treated with only 1
hour of CO pretreatment vs those that received CO preop-
eratively and intraoperatively. No difference in the anes-
thetic recovery time was detected between the groups as
well.
All animals survived the 21 days until the time of
euthanasia, and their weights at that time did not vary
significantly among the groups. No wound complications
required reoperation or antibiotic therapy in any of the
groups. These data support that inhaled CO delivered
perioperatively at a dose of 250 ppm does not have adverse
short-term or long-term effects in pigs.
Effect of combined CO and iNOS gene transfer on
intimal hyperplasia.We have previously reported that NO
delivered through iNOS gene transfer to injured pig iliac
arteries significantly reduced neointima formation.12 The
mechanisms of vasoprotection by NO and CO have many
similarities. We have demonstrated, however, that NO
functions through cGMP-independent pathways, and CO
appears to function through cGMP-dependent ones.9,13,14
If different mechanisms of action are involved, the combi-
Table II. Physiologic parameters
Parameter N Air Pre-op CO
Pre/intra-
op CO
Pre-op weight
(kg)
6 13.9  0.5 14.0  0.5 13.2  0.4
Sacrifice weight
(kg)
6 18.0  1.1 17.5  1.3 16.9  1.1
Intra-op heart rate
(beats/min)
7 82  4 87  4 85  3
Intra-op
respiratory rate
(min)
7 14  2 15  3 14  3
Intra-op oxygen
saturation (%)
7 99  1 98  1 98  1
CO, carbon monoxide.
Statistical analysis by Wilcoxon matched-pair signed-rank test for nonpara-
metric data. There was no statistical difference between any treatment group
in any of these parameters.
Data are presented as mean  standard error.nation of NO and CO may lead to greater vasoprotectionthan either alone. To test this, we performed adenovirus-
mediated iNOS gene transfer within the injured pig CIAs in
combination with inhaled CO delivered for 1 hour preop-
eratively and maintained intraoperatively (Figs 3 and 4,
Table III).
The CIA in all pigs was treated with the control adeno-
viral vector AdlacZ. Inhaled CO reduced intimal areas by
38% and medial area by 25% in AdlacZ-treated vessels (Fig
3, C and D) compared with those treated with air and
AdlacZ (Fig 3, A and B) (P  .001 for both intima and
media areas). Despite the significant reduction in medial
area by CO treatment, the I/M ratio was reduced by 16.4%
by CO compared with air in AdlacZ-infected vessels (P 
.031). The iNOS gene transfer in this study reduced intimal
area by 46% and medial area by 22% (Fig 3, E and F) (P 
.001), which is consistent with our previous studies.12 This
represents a reduction in the I/M ratio of 32% compared
with vessels treated with air and AdlacZ vessels (P .001).
The independent effects of CO and iNOS were similar
and not statistically significant. The combination of CO
and iNOS gene transfer yielded greater reductions in both
intimal (63%) and medial areas (30%) than either CO or
AdiNOS alone (Fig 3, G and H) (P  .001 vs all groups).
Similarly, CO and iNOS reduced the I/M ratio by 48%,
which is significantly lower compared with all other groups
(P  .001). Analysis of these data by the Sheffe test sup-
ports a synergistic effect of CO and iNOS treatments on the
inhibition of neointima formation. These results support
the hypothesis that NO and CO function, at least in part,
through different mechanisms to inhibit the vascular injury
response and the combination of NO and CO delivery
enhances vasoprotection.
DISCUSSION
In this study, we demonstrate that inhaled CO reduced
neointima formation by 35% to 50% in a large-animal
model of vascular injury. This was achieved with a nontoxic
dose of CO of 250 ppm using a clinically feasible treatment
duration. This level of CO exposure did not lead to any
physiologic derangements in heart rate, cardiac rhythm, or
oxygenation during the time of the operation and did not
have adverse effects postoperatively on weight gain or
wound healing. In addition, the combination of inhaled
CO and NO delivered through iNOS gene transfer culmi-
nated in a greater reduction in neointima formation than
either modality alone. This combination of agents also did
not lead to any local or systemic adverse consequences.
The remarkable effectiveness of inhaled CO in inhibit-
ing intimal hyperplasia was evident in rats, where a single
60-minute pretreatment with CO at 250 ppm blocked
neointima formation by about 75%.9 This sharply contrasts
with the findings obtained with inhaled NO, which had to
be administered continuously for the entire 14 days of the
experiment to reduce intimal hyperplasia by 43%.15 In vitro
studies evaluating the effect of CO on smooth muscle cell
proliferation also required that the cells be continuously
exposed to CO for a persistent antiproliferative effect.
These findings all suggest that CO functions very differ-
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NO. Plausible explanations for how CO is functioning in
vivo include direct blunting of the local and systemic in-
Fig 2. Representative cross-sections of pig iliac arter
hematoxylin and eosin (A, C, E) or viewed under autoflu
iliac artery. C-D, Balloon-injured pig iliac artery from a
from a pig treated with 60 minutes of inhaled CO befor
elastic lamina.
Fig 3. Representative cross-sections of pig iliac arteries 3
and gene transfer treatment. Sections were stained w
autofluorescence (B, D, F,H) at4magnification.A-B,
and CO treated. E-F, AdiNOS and oxygen treated.G-H
lamina.flammatory responses to injury, induction of gene productsthat inhibit intimal hyperplasia, or that COHgb behaves as
a reservoir for CO that then slowly releases CO over time.
Which mechanism is involved will be the focus of future
weeks after angioplasty. Sections were stained with
ence (B, D, F) at4 magnification.A-B, Uninjured pig
eated with oxygen. E-F, Balloon-injured pig iliac artery
ery and intraoperative CO. Arrows indicate the internal
ks after angioplasty in combined carbon monoxide (CO)
matoxylin and eosin (A, C, E, G) or viewed under
liac artery treated with AdlacZ and oxygen.C-D,AdlacZ
OS and CO treated.Arrows indicate the internal elasticies 3
oresc
pig tr
e surgwee
ith he
Pig i
, AdiNstudies.
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hyperplasia is a very attractive concept because of the sim-
plicity of its delivery. CO can be administered as an inhala-
tional drug or delivered through an endotracheal tube
during a general anesthetic at the time of surgical interven-
tion, which allows it to be easily incorporated into standard
surgical care. The levels of COHgb achieved with periop-
erative CO delivery were not excessive and were not asso-
ciated with hemodynamic instability or postoperative se-
quelae. Careful toxicity studies will have to be performed to
determine more precisely how CO is tolerated in the pres-
ence of comorbid conditions such as congestive heart fail-
ure and chronic obstructive pulmonary disease, conditions
that are extremely common in patients with vascular dis-
ease.
The combination of CO and iNOS gene transfer
yielded greater inhibition of intimal hyperplasia than either
treatment alone but were not additive. These findings
suggest that CO and NO may share some common vaso-
protective actions but function through distinct pathways
as well. We have previously reported that iNOS gene trans-
fer to vascular smooth muscle cells in vitro blocked prolif-
erative activity through cGMP-independent mechanisms
that involve the upregulation of cyclin-dependent kinase
inhibitors, including p21, and the activation the mitogen-
activated protein kinase (MAPK) extracellular-signal regu-
lated kinase (ERK).14 In contrast, CO-mediated vasopro-
tection in vitro is dependent on cGMP.9 It too upregulated
the cell cycle inhibitor p21 but activated the MAPKs p38
and Jun N-terminal kinase instead of ERK. There was
speculation that COmight induce the expression of endog-
enous iNOS to mediate its vasoprotective functions, but
this proved not to be the case.
Several lines of investigation suggest that both the
HO-1 and NOS pathways may be important in intimal
hyperplasia after vascular interventions, including balloon
Fig 4. Quantification of intimal and medial areas 3 weeks after
balloon injury in pigs treated with AdlacZ or AdiNOS along with
preoperative and intraoperative carbon monoxide (CO) adminis-
tration or air. *P  .001 ves AdlacZ  air; †P  .01 vs AdlacZ 
CO and AdiNOS  air. Data are reported  SEM.angioplasty, vascular stenting, and bypass surgery. Patientswith genetic polymorphisms of the HO-1 gene have higher
rates of in-stent restenosis.16-18 Balloon injury in a rodent
model induces HO-1 expression and CO production,
which acts to limit intimal hyperplasia.19 HO-1 gene trans-
fer has also been shown to reduce intimal hyperplasia in
rodent models.20 The loss of the endothelium as a source of
NO appears to be the basis for the initiation of the vascular
injury response. Simply administering L-arginine, the sub-
strate for the NOS enzymes, significantly reduced intimal
hyperplasia in rodent models of vascular injury.21
It has also been reported that iNOS expression is in-
duced in injured vasculature for several days after injury,22
suggesting that iNOS expression is an adaptive response to
limit neointima formation. Certainly, there is abundant
literature reporting the beneficial effects of NOS overex-
pression at sites of angioplasty and stenting and after bypass
in both small-animal and large-animal models.23-25
NO and CO often coexist in many tissues and may
influence each other’s production and actions. Zucker-
braun et al26 demonstrated in hepatocytes that protection
from apoptosis mediated by CO required iNOS expression,
and alternatively, the protective effect of NO required
HO-1 activation. NO can upregulate the expression of
HO-1,27 and CO can regulate iNOS function by binding
to its heme moiety.28 In the vasculature, however, the
interdependence between CO and NO is not so evident.
Smooth muscle cells treated with NO donors29 increase
HO-1 expression and CO production. Kong et al30 dem-
onstrated that balloon-injured vessels seededwith endothe-
lial progenitor cells overexpressing HO-1 failed to provide
added benefit over control EPCs in reducing IH,30 whereas
those overexpressing endothelial NOS inhibited intimal
hyperplasia by an additional 24%. Others have demon-
strated that HO-1 transfection of injured vessels stimulated
vascular relaxation through cGMP but independent of
NO.31 Interestingly, the synergistic potential of CO and
NO was suggested by another study that showed low-dose
CO could release NO from intracellular stores.32
CONCLUSION
Perioperatively administered inhaled CO reduces the
formation of neointima after angioplasty in a large-animal
model. There was no evidence of adverse alterations in
hemodynamics or in postoperative recovery. The combina-
tion of CO and NO, administered through iNOS gene
transfer, further inhibited intimal hyperplasia. The combi-
nation of CO and NO also did not result in toxicity to the
pigs, albeit a formal toxicology review was not performed.
Although the mechanisms of protection provided by each
of these agents are not fully understood, it is clear from the
synergistic benefit of the combined therapy that they func-
tion through common as well as unique pathways. Further
investigation will be required to determine if combining
these treatments will allow reduction in the doses of both
agents to provide the safest therapy possible and increase
the ability of patients with numerousmedical comorbidities
to tolerate this very effective regimen.
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